Outlook Therapeutics (OTLK) Cost of Revenue (2025 - 2026)

Outlook Therapeutics (OTLK) reported Cost of Revenue of $149327.0 for Q1 2026, up 404.04% quarter-over-quarter from $29626.0 in Q4 2025.

Outlook Therapeutics (OTLK) Cost of Revenue (2025 - 2026) Analysis & Trends

Outlook Therapeutics (OTLK) has 2 years of Cost of Revenue data on file, last reported at $149327.0 in Q1 2026.

Cost of Revenue for Q1 2026 came in at $149327.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (changed N/A YoY), and the FY2025 annual result was $1.4 million, changed N/A from the prior year.
Cost of Revenue rose to $149327.0 in Q1 2026 per OTLK's latest filing, from $29626.0 in the prior quarter.
Over five years, Cost of Revenue peaked at $916515.0 in Q3 2025 and troughed at $29626.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	64.20 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	48,670.00
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	392.80 Mn
9	Abivax	94.37 Bn	94.37 Bn	-	2.05 Mn
10	Outlook Therapeutics	51.56 Mn	43.81 Mn	-21,888.00	149,327.00

Download Data